Arrowhead Pharmaceuticals stock hits 52-week high at 84.65 USD
Arrowhead Pharmaceuticals (ARWR) reached a new 52-week high of $84.65, demonstrating a 400% 1-year return and a current market cap of $11.83 billion. Despite trading above its Fair Value, investor confidence remains high due to advancements in its therapeutic pipeline. The company recently reported better-than-expected Q2 FY2026 results and received a reiterated "buy" rating from H.C. Wainwright.
Price to book forward of Arrowhead Pharmaceuticals, Inc. – NASDAQ:ARWR
This article displays the "Price to book forward" metric for Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) on TradingView. It provides a quick financial overview for the company, indicating the market is currently closed with no trades. The content primarily serves as a snapshot of a single financial data point within the broader TradingView platform.
Enterprise value to EBIT forward of Arrowhead Pharmaceuticals, Inc. – NASDAQ:ARWR
The article presents financial information for Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), specifically focusing on its enterprise value to EBIT forward. It appears to be an analysis page from TradingView, providing an overview of the company's financial data.
Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh
This page provides financial data specifically the "Price to earnings forward" for Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt, trading under the symbol A2RR34 on the B3 stock exchange. The information is presented by TradingView, detailing various metrics. The article also mentions the market status, which is currently closed with no trades.
Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh
This article focuses on the price-to-book forward ratio for Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt (A2RR34) listed on the BMFBOVESPA. It provides a snapshot of the instrument's financial overview, noting that the market is currently closed with no trades. The content primarily highlights the financial metric within the TradingView platform context.
Price to sales forward of Arrowhead Pharmaceuticals, Inc. – NASDAQ:ARWR
This article focuses on the "Price to sales forward" metric for Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR). It appears to be a financial data snippet from TradingView, indicating the value and change of this specific financial ratio for the company over a particular period. The content itself is very minimal, presenting only the metric's title and placeholders for its value and change.
H.C. Wainwright reiterates Arrowhead Pharma stock rating at buy
H.C. Wainwright reiterated a buy rating and $100 price target for Arrowhead Pharmaceuticals after the company's cardiometabolic R&D webinar. Arrowhead's stock has seen a significant 376% gain over the past year, trading near its 52-week high, and analysts maintain a bullish consensus. Key catalysts include Phase 3 readouts for REDEMPLO and enrollment completion for zodasiran's Phase 3 YOSEMITE trial in 2026.
H.C. Wainwright reiterates Arrowhead Pharma stock rating at buy By Investing.com
H.C. Wainwright has reiterated a buy rating and $100 price target for Arrowhead Pharmaceuticals (NASDAQ:ARWR) following a cardiometabolic R&D webinar. The stock has seen a significant 376% gain over the past year, trading near its 52-week high, and Wall Street analysts maintain a bullish outlook. Key upcoming catalysts include Phase 3 readouts for REDEMPLO, expected in Q3 2026, and the completion of zodasiran’s Phase 3 enrollment.
H.C. Wainwright reiterates Arrowhead Pharma stock rating at buy By Investing.com
H.C. Wainwright has reiterated a buy rating and a $100 price target for Arrowhead Pharmaceuticals after the company's cardiometabolic research and development webinar. Arrowhead Pharmaceuticals' stock is currently trading near its 52-week high, having gained 376% over the past year. Analysts maintain a bullish consensus, with upcoming catalysts including Phase 3 readouts for REDEMPLO and the completion of zodasiran’s Phase 3 YOSEMITE enrollment.
Arrowhead Pharmaceuticals Is Maintained at Buy by Chardan Capital
Chardan Capital has reiterated its Buy rating on Arrowhead Pharmaceuticals, indicating a continued positive outlook on the company's stock. This maintenance of rating suggests the firm's confidence in Arrowhead's future performance or pipeline.
A Quick Look at Today's Ratings for Arrowhead Pharmaceuticals(ARWR.US), With a Forecast Between $90 to $110
This article provides a brief overview of recent analyst ratings for Arrowhead Pharmaceuticals (ARWR.US). The forecast for the company's stock is between $90 and $110.
Chardan Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $90
Chardan Capital has reiterated its Buy rating for Arrowhead Pharmaceuticals (ARWR.US) and maintained a target price of $90. This indicates a continued positive outlook from the firm regarding the company's stock performance and potential.
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell 3000E Value Benchmark
Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) has been added to the Russell 3000E Value Benchmark, effective June 28, 2026. This inclusion is part of several Russell index adjustments for the company, which also saw it added to the Russell Midcap Value, Russell 1000 Value, Russell 1000 Growth, and Russell Midcap Index, while being dropped from the Russell 2000 and Russell 2000 Growth benchmarks. The company focuses on developing RNAi therapies for intractable diseases, with a pipeline of over 18 drug candidates in various clinical trial stages.
Arrowhead Pharmaceuticals, Inc.(NasdaqGS: ARWR) dropped from Russell 2000 Index
Arrowhead Pharmaceuticals, Inc. (ARWR) has been removed from the Russell 2000 Index. This significant event for the biotechnology company was published on June 29, 2026, at 2:37 pm EDT. Despite this news, the company's stock showed a 2.04% increase on the day this announcement was made.
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell 1000 Growth Benchmark
Arrowhead Pharmaceuticals (NasdaqGS:ARWR) has been added to the Russell 1000 Growth Benchmark. This move comes after the company was dropped from the Russell 2000 Growth Benchmark and added to the Russell 1000 Value Benchmark. The biotechnology company focuses on developing medicines for intractable diseases using RNA interference.
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $100
H.C. Wainwright has reiterated its Buy rating on Arrowhead Pharmaceuticals (ARWR.US), maintaining a target price of $100. This continued endorsement suggests confidence in the company's future performance and stock value.
Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh
This page provides financial actuals and estimates for Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh (BMFBOVESPA: A2RR34) on TradingView. Users can explore reported financial data, analyst estimates across various financial statements, and visualize trends over time. The platform also offers tools for comparing actual results with average, high, and low estimates.
Arrowhead Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ARWR)
This article provides an overview of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), including its current stock price, historical performance, analyst forecasts, and financial data. It highlights the company's significant growth over the last year, its market capitalization, recent earnings, and upcoming earnings report. The piece also addresses frequently asked questions about buying ARWR stock and its investment potential.
Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Arrowhead Pharmaceuticals announced that the European Commission has granted marketing authorization for REDEMPLO® (plozasiran) to treat adults with familial chylomicronemia syndrome (FCS). This siRNA medicine, the first and only authorized by the EC for FCS, does not require genetic confirmation, potentially enabling earlier treatment. Clinical data from the Phase 3 PALISADE study supported the approval, demonstrating an 80% reduction in triglycerides and an 83% reduction in acute pancreatitis incidence.
Arrowhead Pharmaceuticals gets EC approval for REDEMPLO in FCS
Arrowhead Pharmaceuticals has received European Commission marketing authorization for REDEMPLO (plozasiran), an siRNA medicine to treat familial chylomicronemia syndrome (FCS) in adults. This marks the first such approval for an siRNA medicine in the EU for FCS patients. The approval was supported by data from the Phase 3 PALISADE study, which showed significant triglyceride reduction and a decreased incidence of acute pancreatitis.
Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Arrowhead Pharmaceuticals announced that the European Commission has granted marketing authorization for REDEMPLO® (plozasiran) to treat familial chylomicronemia syndrome (FCS) in adults. This siRNA medicine is the first authorized treatment for FCS that does not require genetic confirmation, addressing a significant unmet medical need. The approval is based on positive Phase 3 PALISADE study data, showing an 80% reduction in triglycerides and an 83% reduction in acute pancreatitis incidence, offering renewed hope for patients suffering from this severe rare disease.
EU approves Arrowhead's REDEMPLO for rare fat disorder FCS
Arrowhead Pharmaceuticals has received marketing authorization from the European Commission (EC) for REDEMPLO (plozasiran) to treat Familial Chylomicronemia Syndrome (FCS) in adults. This is the first and only siRNA medicine authorized by the EC for FCS that does not require genetic confirmation, addressing a significant unmet medical need. The approval is based on positive Phase 3 PALISADE study data, showing REDEMPLO reduced triglycerides by 80% and acute pancreatitis incidence by 83%.
The Insider Report: Stocks Celebrate Peace and a New Fed Chapter
This "Insider Report" highlights the recent positive market reaction to a peace deal with Iran and the new Fed Chairman Kevin Warsh's hawkish tone. It provides bullish outlooks and action plans for three specific stocks: MDA Space (MDA), Arrowhead Pharmaceuticals (ARWR), and Adeia (ADEA), detailing their recent performance, financials, technical analysis, and growth catalysts. The report also discusses broader market trends, including sector leadership, the emerging AI phase in biotech, and signals from the bond market regarding inflation and the yield curve, while noting the bearish trend in cryptocurrency.
Arrowhead Pharmaceuticals (ARWR) Stock Could Be 25.6% Undervalued After R And D Webinar Update
Arrowhead Pharmaceuticals' recent R&D webinar and clinical updates have led to strong stock momentum, with a 45.3% increase over three months, yet analysis suggests it could still be 25.6% undervalued according to one valuation model. However, another view focusing on its P/S ratio indicates potential overvaluation compared to the industry and peers. Investors are encouraged to consider these mixed signals and conduct further research beyond a single narrative.
Are Arrowhead Pharmaceuticals’ (ARWR) Board Moves and RNAi Webinars Quietly Reframing Its Risk Narrative?
Arrowhead Pharmaceuticals recently appointed Dr. Matt Cohen to its board and announced an R&D webinar series, highlighting its TRiM-based RNAi pipeline. These moves are seen as strengthening the company's capital markets expertise and increasing visibility for its cardiometabolic pipeline, but do not fundamentally alter its investment narrative of managing losses and partner dependence. The article explores how these developments might subtly influence the perception of Arrowhead's risk profile and future prospects.
Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced it will host a 2026 Summer Series of R&D webinars focusing on its RNA interference (RNAi) based medicines. Part I, scheduled for June 29, 2026, at 11:30 AM EDT, will highlight the company's cardiometabolic pipeline. The webinar will feature presentations from Arrowhead team members and external key opinion leaders, including Steven Nissen, M.D., from the Cleveland Clinic.
Arrowhead Pharmaceuticals stock hits 52-week high at $82.30
Arrowhead Pharmaceuticals Inc. (ARWR) stock reached a new 52-week high of $82.30, trading near its peak with a 394% increase over the past year and a market capitalization of $11.5 billion. Despite this, InvestingPro analysis suggests the stock might be overvalued relative to its Fair Value. The company also reported better-than-expected Q2 FY2026 results and positive interim clinical trial data for its therapeutic candidates.
Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars
Arrowhead Pharmaceuticals announced a 2026 Summer Series of R&D webinars highlighting its clinical-stage RNA interference (RNAi) based medicines. The first webinar, focusing on the cardiometabolic pipeline, is scheduled for June 29, 2026, at 11:30 AM EDT and will feature presentations from company team members and Dr. Steven Nissen from the Cleveland Clinic. The series will cover specific therapeutic areas, including detailed discussions on current clinical candidates like Plozasiran (APOC3) and Zodasiran (ANGPTL3).
Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars
Arrowhead Pharmaceuticals announced a 2026 Summer Series of R&D webinars to highlight its clinical stage RNA interference (RNAi) based medicines. The first webinar, focusing on its cardiometabolic pipeline, is scheduled for June 29, 2026, at 11:30 AM EDT and will feature presentations from company team members and Dr. Steven Nissen of the Cleveland Clinic. The event will cover an overview of the cardiometabolic pipeline, Arrowhead's technology, specific drug candidates like Plozasiran and Zodasiran, and the treatment landscape for Mixed Hyperlipidemia & ASCVD.
Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced a 2026 Summer Series of R&D webinars focusing on its RNA interference (RNAi) based medicines. Part I, scheduled for June 29, 2026, at 11:30 AM EDT, will highlight the company's cardiometabolic pipeline. The webinar will feature presentations from Arrowhead management and external key opinion leaders, including Steven Nissen, M.D., discussing the treatment landscape for mixed hyperlipidemia and ASCVD.
Arrowhead Pharmaceuticals Inc
The TradingKey platform provides an overview of Arrowhead Pharmaceuticals Inc. (ARWR), including its stock quote, market capitalization, and P/E TTM. However, the article explicitly states that relevant data for revenue breakdown by business segments and regions has not yet been disclosed by the company. The page also features general information about the company and disclaimers about investment risks.
Arrowhead Pharmaceuticals (ARWR) director files Form 3 showing zero share ownership
Arrowhead Pharmaceuticals director Matthew Gregory Cohen has filed an initial Form 3 with the SEC, indicating he currently holds zero shares of the company's Common Stock. This filing serves as a baseline disclosure for him as a newly reported insider and does not represent a buy or sell transaction. The Form 3 details his direct ownership of 0 common shares, establishing his initial position.
Director Matthew Cohen granted 11,882 RSUs at Arrowhead Pharmaceuticals (ARWR)
Arrowhead Pharmaceuticals director Matthew Gregory Cohen was granted 11,882 Restricted Stock Units (RSUs) on June 15, 2026, at no cash cost. These RSUs will vest over three years, aligning his compensation with the company's long-term performance. Following this grant, Cohen directly holds 11,882 shares of Arrowhead Pharmaceuticals Common Stock.
Arrowhead Pharmaceuticals Inc (ARWR) Financial Health: Profitability & Balance Sheet Analysis
Arrowhead Pharmaceuticals Inc (ARWR) currently holds a financial score of 6.99, ranking 171 out of 388 in the Biotechnology & Medical Research industry, indicating a weak financial status but high operating efficiency. The company reported a significant year-over-year decrease of 86.41% in its latest quarterly revenue and a 135.83% decrease in net profit. Most specific financial metrics like cash and equivalents, total assets, revenue, and operating profit have not been disclosed by the company yet.
A Veteran healthcare investor Matt Cohen joins Arrowhead (ARWR) board with $887K RSU grant
Arrowhead Pharmaceuticals, Inc. has appointed Dr. Matt Cohen, a veteran healthcare investor with over 25 years of experience, to its Board of Directors, effective June 12, 2026. Dr. Cohen will receive standard non-employee director compensation and a sign-on grant of restricted stock units valued at $887,000, vesting over three years. This appointment is noted to have no family relationships or special arrangements, and Dr. Cohen will enter into the company's standard indemnity agreement.
Is Arrowhead Pharmaceuticals on the Cusp of a Major Breakout
Arrowhead Pharmaceuticals is nearing a critical juncture with Phase 3 data for plozasiran in severe hypertriglyceridemia (SHTG) expected in Q3 2026, which could significantly expand its market beyond familial chylomicronemia syndrome (FCS). The company boasts a strong financial position with $1.8 billion in cash and strategic licensing deals, providing a solid foundation for its pipeline and commercialization. While successful SHTG data could unlock substantial further upside, the market's high expectations mean execution risks remain.
Why (ARWR) Price Action Is Critical for Tactical Trading
This article analyzes Arrowhead Pharmaceuticals Inc. (ARWR) with a focus on tactical trading due to divergent sentiment across all horizons. It identifies a mid-channel oscillation pattern and presents three distinct AI-generated trading strategies: Long Position, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis. The report highlights an exceptional risk-reward setup targeting a 16.6% gain.
Alpha-1 Antitrypsin Deficiency Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Grifols, Kamada Pharma, Takeda, Arrowhead Pharma, Mereo BioPharma, AstraZeneca, Sanofi
The Alpha-1 Antitrypsin Deficiency (AATD) market, valued at approximately USD 940 million in 2024 across the 7MM, is projected for significant growth by 2036. This expansion is driven by increasing adoption of approved treatments, advancements in gene therapy and RNA-editing, and the anticipated launch of innovative emerging therapies. Key market players like Grifols, Kamada Pharmaceuticals, Takeda, and others are actively developing new treatments, including BEAM-302 and KRRO-110, which aim to offer more durable and less invasive options for patients.
Arrowhead Pharmaceuticals, Inc. Trade Ideas — XETR:HDP1
This article compiles several trading ideas and analyses for Arrowhead Pharmaceuticals, Inc. (XETR:HDP1, NASDAQ:ARWR). Contributors discuss various technical patterns such as flag patterns, stair-step patterns, "cup and handle" formations, and potential reversals, along with fundamental news like the Amgen partnership. Analysis includes price targets, stop-loss recommendations, and observations on volume and institutional accumulation.
Arrowhead Pharmaceuticals, Inc. Trade Ideas — XETR:HDP1
Arrowhead Pharmaceuticals (HDP1, ARWR) saw its stock spike over 23% following an earnings beat and the FDA approval of its drug Redemplo for familial chylomicronemia syndrome (FCS). The company reported significant revenue growth for fiscal year 2025, reaching $829 million, primarily from licensing and collaboration funds. Various traders offer analyses and predictions for ARWR, ranging from bullish movements based on technical indicators and pipeline strength, to short-term bearish outlooks due to overbought conditions or resistance levels.
Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction
Arrowhead Pharmaceuticals is preparing to release topline data for plozasiran (SHASTA-3 and SHASTA-4 studies) in severe hypertriglyceridemia in the third quarter, expressing cautious optimism. The launch of REDEMPLO for familial chylomicronemia syndrome is gaining momentum, showing better early uptake than a comparable competitor due to its reduced price and positive payer feedback. The company is actively advancing several other pipeline programs in obesity, MASH, CNS, and lipid disorders, with multiple upcoming catalysts, while remaining focused on siRNA therapeutics.
ARWR News | ARROWHEAD PHARMACEUTICALS IN (NASDAQ:ARWR)
This article provides recent news and analysis for Arrowhead Pharmaceuticals (NASDAQ:ARWR), highlighting its stock performance, recent drug launches, and participation in industry events. It includes financial updates such as strong Q2 earnings, revenue beats, and a report of its first FDA approval. The company is also presenting new clinical data for its RNAi-based candidates.
Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events
Arrowhead Pharmaceuticals, Inc. announced its participation in two upcoming healthcare conferences in June 2026: the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. The company will present in fireside chats at both events, with presentation materials and webcasts available on its investor relations website. Arrowhead Pharmaceuticals is a commercial-stage pharmaceutical company focused on developing RNA interference (RNAi) therapeutics for intractable diseases.
Arrowhead Pharmaceuticals Drops 7.0% Amid Sector-Wide Selling
Arrowhead Pharmaceuticals (ARWR) saw its stock price drop by 7.0% on Tuesday, closing at $69.95, as the biotechnology sector experienced a broad selloff. This decline was part of a wider downdraft affecting several peer companies, indicating a sector-wide investor rotation rather than company-specific issues for Arrowhead. Investors are advised to monitor whether this sector weakness will persist or if broader market catalysts might reverse the sentiment.
Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced its participation in two upcoming June 2026 events. The company will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. These presentations will be "Fireside Chat" type presentations, with dates and times provided.
Arrowhead Pharmaceuticals eyes Q3 SHASTA data as REDEMPLO approvals build momentum
Arrowhead Pharmaceuticals is anticipating Q3 data from its SHASTA trial. This comes as approvals for its drug REDEMPLO are gaining momentum. The company is focused on advancing its pipeline with these key developments.
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After New Plozasiran And ARO INHBE Clinical Results
Arrowhead Pharmaceuticals, Inc. (ARWR) is gaining investor attention due to positive clinical data for plozasiran and ARO-INHBE, leading to a significant increase in its share price. While one market narrative suggests the stock is 23.3% overvalued with a fair value of $64.08, a discounted cash flow model indicates it could be significantly undervalued at $179.12 per share compared to its current price of $78.99. Investors are urged to consider both sides of the valuation given the dependence on future clinical trial readouts and partnership milestones.
Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
Arrowhead Pharmaceuticals presented new interim results from a Phase 1/2a clinical trial of ARO-INHBE, an RNAi therapeutic for obesity and MASH, at EASL 2026. The data show that ARO-INHBE significantly reduced liver fat as both a monotherapy and in combination with low-dose tirzepatide in obese adults, with continued improvements seen with longer exposure. The company is engaging with regulatory authorities for future Phase 2 studies, highlighting the potential of targeting the Activin E/ALK7 pathway for metabolic dysfunction.
Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotech’s Solid Start to 2026
Bernstein has increased its price target for Arrowhead Pharmaceuticals (ARWR) to $46 from $35, while maintaining a Market Perform rating. This adjustment follows a strong start to 2026 for the biotech sector, with ARWR outperforming the market. The company also reported positive momentum for its REDEMPLO® commercial events, showing significant growth in prescriptions and patient adoption.
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
Arrowhead Pharmaceuticals shared new clinical data for plozasiran at the 94th European Atherosclerosis Society Congress, demonstrating its potential use in patients with moderate-to-severe renal or moderate hepatic impairment without dose adjustment. The data also included a case report suggesting that preconception exposure to plozasiran may lead to sustained lowering of fasting triglyceride levels throughout pregnancy. Plozasiran, an siRNA medicine, targets APOC3 to reduce triglycerides and is currently approved in several countries for Familial Chylomicronemia Syndrome (FCS), with ongoing investigations for severe hypertriglyceridemia.
